CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
QR-110drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03140969
NCT03140969Phase 2Completed
CompareCT.gov

An Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Laboratoires Thea·interventional·Posted May 4, 2017·Updated Oct 15, 2024

In Brief

A Phase 2 clinical trial evaluating QR-110 for Leber's Congenital Amaurosis. Completed, enrolled 11 participants across 3 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeber's Congenital Amaurosis
CountriesBelgium, United States
CollaboratorsSepul Bio

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 4, 2017
Enrollment StartOct 16, 2017
Primary CompletionOct 2, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.2 years ago

Interventions

QR-110drug

RNA antisense oligonucleotide for intravitreal injection